CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd...
Phase 2
Austin, Texas, United States and 57 other locations
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer...
Phase 3
Austin, Texas, United States and 805 other locations
ovarian function in premenopausal women with HR+, HER2-negative breast cancer and men with HR+ breast cancer. The...
Phase 3
New Braunfels, Texas, United States and 10 other locations
growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine ...
Phase 3
Austin, Texas, United States and 293 other locations
in patients with advanced solid tumors or in combination with anti-cancer agents such as CDK 4/6 inhibitor palbociclib in patients with ER+/ ...
Phase 1, Phase 2
Austin, Texas, United States and 3 other locations
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo a...
Phase 3
Austin, Texas, United States and 70 other locations
adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurren...
Phase 3
Austin, Texas, United States and 528 other locations
treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and arom...
Phase 3
Austin, Texas, United States and 217 other locations
receptor-low/HER2-negative breast cancer....
Phase 3
Austin, Texas, United States and 338 other locations
with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who received at least 2 prior treatments, at...
Phase 2
Austin, Texas, United States and 21 other locations
Clinical trials
Research sites
Resources
Legal